Start free
← Back to Current AffairsRAS Pre 2026 Answer KeyExam on 6 December 2026: answer key, question paper PDF and solutions on exam day →
Current Affairs · 29 October 2026

Relief: Cancer Drugs Across 543 Brands to Get Cheaper from 9 November; NPPA Caps Trade Margin on 137 Anti-Cancer Drugs at 30%

RPSC RASRajasthan PatrikaSource: Rajasthan Patrika (Jaipur e-paper, 29 Oct 2026)
1

Why in News

  • The National Pharmaceutical Pricing Authority (NPPA) has changed the prices of 543 brands of cancer medicines, as reported by Rajasthan Patrika on 29 October 2026.
  • The revised prices will come into effect from 9 November, giving relief to lakhs of cancer patients undergoing treatment.
  • NPPA has capped the trade margin on 137 anti-cancer drugs at 30%, which will make many drugs cheaper by 80 to 90%.
  • The decision comes amid ongoing Supreme Court hearings on controlling medicine prices, which form the immediate trigger for the move.
  • After the cut, one drug's vial priced at Rs 80,072 will be available for Rs 7,150.
2

What is the issue

  • Cancer treatment in India is expensive, and the cost of anti-cancer drugs is a major barrier for patients, making price regulation a public-health priority.
  • The NPPA, the statutory body under the Drugs (Prices Control) Order framework, fixes and revises prices of scheduled formulations and monitors margins.
  • The core mechanism here is a cap on trade margin — the difference between the price to the consumer and the price at which the manufacturer sells to the trade.
  • Capping trade margin at 30% on 137 anti-cancer drugs attacks the margin layer rather than the manufacturing cost, a route used earlier for other non-scheduled medicines.
  • The matter is being heard in the Supreme Court, indicating judicial scrutiny of drug pricing and affordability of essential medicines.
  • Stakeholders include cancer patients and their families, manufacturers and trade channels, the NPPA as regulator, and the Union government.
  • The article notes that some expensive drugs, such as immunotherapy drugs, have not yet seen a price cut, showing the reform is partial.
  • For governance, the issue links medicine affordability to the right to health, out-of-pocket expenditure and the burden on households.
  • For the economy, cheaper cancer drugs reduce catastrophic health spending, though the article does not quantify this.
Detailed analysis

The full analysis is in the app

This page is the summary. The detailed analysis of this story covers:

What is the statusWhat are the challengesWhat measuresWhat lies aheadImportant Data PointsKey conceptsPrevious year questions
Open in Quorum IAS